Xbrane Biopharma AB (publ) (“Xbrane” or “the company”) announces the appointment of Anette Lindqvist as Chief Financial Officer & Head of Investor Relations effective today.

Anette brings extensive experience from Senior Finance & Business Roles in the Life Science sector such as AstraZeneca, Mölnlycke Healthcare and Getinge Infection Control. Her education includes studies at Gothenburg School of Economics, tax & auditing as well as leadership and business development. Anette replaces Margareta Hagman, interim CFO, whom will be available during a transition period.
 
“I want to welcome Anette to Xbrane and I am confident her expertise will contribute significantly to Xbrane’s development and growth” Martin Åmark, CEO Xbrane says. “I also want to thank Margareta Hagman and wish her all the best for her future endeavours”

Contacts

Martin Åmark, CEO
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.

Attachments

Xbrane appoints Anette Lindqvist as new Chief Financial Officer & Head of Investor Relations

© Modular Finance, source Nordic Press Releases